Chemocentryx, Inc. is a company in the U.S. stock market and it is a holding in 40 U.S.-traded ETFs. CCXI has around 2.2M shares in the U.S. ETF market. The largest ETF holder of CCXI is the iShares NASDAQ Biotechnology ETF (IBB), with approximately 547.87K shares. Investors may also find of interest that the ETF with the largest allocation to CCXI stock is ALPS Medical Breakthroughs ETF (SBIO), with a portfolio weight of 3.03%. On average, U.S. ETFs allocate 0.45% of CCXI to their portfolios.

Additionally, CCXI is a favorite stock for Vanilla and Multi-factor ETFs. It is also most likely to belong to Broad-based ETFs. The best-performing ETF in the past 12 months with CCXI as a holding is the Virtus LifeSci Biotech Clinical Trials ETF (BBC), with a return of 27.53%.